Baird Maintains Neutral on Mersana Therapeutics, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Colleen Kusy maintains a Neutral rating on Mersana Therapeutics (NASDAQ:MRSN) and lowers the price target from $4 to $3.
August 14, 2024 | 11:41 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Baird analyst Colleen Kusy maintains a Neutral rating on Mersana Therapeutics and lowers the price target from $4 to $3.
The lowered price target from $4 to $3 by Baird suggests a less optimistic outlook for Mersana Therapeutics, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100